Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL28367559 | 0.91 | ALDH1A1 (0.39) | GSK3BALDH1A1KDM4EHSD17B10ITGA4 | |
| SCHEMBL16098960 | 0.79 | SMN1; SMN2 (0.44) | GSK3BALDH1A1KDM4EHSD17B10ITGA4 | |
| SCHEMBL30603810 | 0.78 | GSK3B (0.52) | GSK3BALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL18113497 | 0.78 | GSK3B (0.52) | GSK3BALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL23836741 | 0.78 | GSK3B (0.41) | GSK3BALDH1A1KDM4EHSD17B10ITGA4 | |
| SCHEMBL18510249 | 0.76 | ALDH1A1 (0.40) | GSK3BALDH1A1KDM4EHSD17B10ITGA4 | |
| SCHEMBL18113468 | 0.76 | KDM4E (0.40) | GSK3BALDH1A1KDM4EHSD17B10ITGA4 | |
| SCHEMBL30603804 | 0.76 | KDM4E (0.40) | GSK3BALDH1A1KDM4EHSD17B10ITGA4 | |
| SCHEMBL10602199 | 0.76 | GSK3B (0.48) | GSK3BALDH1A1KDM4EHSD17B10ITGA4 | |
| SCHEMBL10602710 | 0.75 | ALDH1A1 (0.43) | GSK3BALDH1A1KDM4EHSD17B10ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253252-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | claimed |
| CN-114516856-B | Dihydro-isoquinolinone and isoindolinone derivatives and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| CN-118307521-A | Pyrimidine PLK1 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11998901-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | INSTITUTE FOR BASIC SCIENCE (KR) | 2024-06-04 | — | — | US | disclosed |
| CN-118084892-A | Compounds useful as HPK1 inhibitors | 深圳福沃药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024051717-A1 | COMPOUND AS PLK1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117658987-A | Compounds as PLK1 inhibitors, and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| US-6583144-B2 | Piperazine substituted isoquinoline, 1,3-benzoxazine, or 1,3-benzothiazine derivatives; inhibitors against the biosynthesis of triglycerides and secretion of apolipoprotein b and treatment of hyperlipidemia | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | OHKURA NAOTO (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6417362-B1 | PIPERAZINE DERIVATIVES; ARTERIOSCLEROSIS, PANCREATITIS, AND CARDIOVASCULAR DISORDER TREATMENT; SIDE EFFECT REDUCTION | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| EP-0999208-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND HYPERLIPEMIA REMEDY CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-5962469-A | PREVENTION OF OXIDATION TISSUE DAMAGE BY FREE RADICALS | HOECHST MARION ROUSSEL INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0863878-A1 | CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST MARION ROUSSEL, INC. (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997010218-A1 | CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST MARION ROUSSEL, INC. (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | APOB, PNLIP, NR1H2 | GSK3B 3024/4885ALDH1A1 3399/4885KDM4E 3344/4885 |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | GSK3B 675/4885ALDH1A1 2954/4885KDM4E 1228/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | GSK3B 689/4885ALDH1A1 1369/4885KDM4E 4317/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | GSK3B 1677/4885ALDH1A1 3576/4885KDM4E 1997/4885 |
| US-11998901-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | COASY, NOTUM, MRPL21 | GSK3B 1827/4885ALDH1A1 2316/4885KDM4E 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.